TREATMENT UPDATE: Daratumumab (also known as Darzalex®) recommended across Europe in new combinations for myeloma patients.
The Committee of Human Medicinal Products in Europe is recommending that daratumumab (also known as Darzalex®) has its licence extended to include combination treatments for myeloma patients.
It's already licensed in Europe for use on its own.
The Committee of Human Medicinal Products in Europe is recommending that daratumumab (also known as Darzalex®) has its licence extended to include combination treatments for myeloma patients.
It's already licensed in Europe for use on its own.